Skip to Main Content

Advertisement

Skip Nav Destination

Gut microbiota exploitation by CPX-351 in AML; optimizing anti-myeloma immunity for ASCT; which pediatric ITP patients will develop lupus?

In this week's episode, we'll discuss gut microbiota exploitation by CPX-351 in acute myeloid leukemia. Then we'll learn about optimizing anti-myeloma immunity. New research shows that regulatory T cells suppress myeloma-specific immunity during autologous stem cell mobilization and transplantation. Finally we'll discuss among pediatric patients with ITP or other autoimmune cytopenias, which ones will go on to develop systemic lupus?

Released April 18, 2024

Subscribe today via iTunes   Google Play    Spotify to receive notification of each new episode as it's published.

 

The articles highlighted in this episode are listed below:

 
Close Modal

or Create an Account

Close Modal
Close Modal

Advertisement